Search
Now showing items 1-4 of 4
Ethics of Early Intervention in Alzheimer’s Disease
(2021-03)
Alzheimer’s disease (AD) research, treatment, and prevention focus increasingly on developing personalized interventions based on personal genetic, biological, phenotypic data, for
early intervention (EI) to limit harm. ...
Quantification of allosteric communications in matrix metalloprotease-1 on alpha-synuclein aggregates and substratedependent virtual screening
(2021-01)
Alpha-synuclein (aSyn) has implications in pathological protein aggregations observed in
neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. There are currently
no approved prevention and cure ...
Quantifying the heterogeneity of cognitive functioning in Alzheimer’s disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil
(2021-02)
Background. The extent and profiles of heterogeneity in cognitive functioning among participants in clinical trials of antidementia medication are unknown. We aimed to quantify and
identify profiles of heterogeneity of ...
Neurons derived from individual early Alzheimer’s disease patients reflect clinical vulnerability
(2021-11)
Modelling sporadic Alzheimer’s disease (sAD) with patient-derived induced pluripotent stem
cells (iPSCs) is challenging yet remains an important step in understanding the disease. Here
we report a novel approach of sAD ...